Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Hepatitis C

  Free Subscription


3 Eur J Gastroenterol Hepatol
2 Hepatology
1 J Gastroenterol
1 J Hepatol
1 J Med Virol
2 J Viral Hepat
3 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Eur J Gastroenterol Hepatol

  1. ISMAIL WA, Yousef AE
    Effect of sofosbuvir plus daclatasvir for treatment of chronic hepatitis C on patients with psoriasis.
    Eur J Gastroenterol Hepatol. 2019 Jan 29. doi: 10.1097/MEG.0000000000001370.
    PubMed     Text format     Abstract available

  2. STOURNARAS E, Neokosmidis G, Stogiannou D, Protopapas A, et al
    Effects of antiviral treatment on the risk of hepatocellular cancer in patients with chronic viral hepatitis.
    Eur J Gastroenterol Hepatol. 2018 Sep 1. doi: 10.1097/MEG.0000000000001254.
    PubMed     Text format     Abstract available

  3. VAN SANTEN DK, Schim van der Loeff MF, Cartier van Dissel J, Martens JPD, et al
    High proportions of liver fibrosis and cirrhosis in an ageing population of people who use drugs in Amsterdam, The Netherlands.
    Eur J Gastroenterol Hepatol. 2018;30:1168-1176.
    PubMed     Text format     Abstract available


  4. ZEUZEM S, Bourgeois S, Greenbloom S, Buti M, et al
    JNJ-4178 (AL-335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus-infected Patients without Cirrhosis: OMEGA-1.
    Hepatology. 2019 Jan 28. doi: 10.1002/hep.30527.
    PubMed     Text format     Abstract available

  5. HUANG AC, Mehta N, Dodge JL, Yao FY, et al
    Direct-acting Antivirals Do Not Increase the Risk of Hepatocellular Carcinoma Recurrence after Local-Regional Therapy or Liver Transplant Waitlist Dropout.
    Hepatology. 2018 Feb 24. doi: 10.1002/hep.29855.
    PubMed     Text format     Abstract available

    J Gastroenterol

  6. DOI A, Hikita H, Kai Y, Tahata Y, et al
    Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    J Gastroenterol. 2019 Jan 25. pii: 10.1007/s00535-018-01541.
    PubMed     Text format     Abstract available

    J Hepatol

  7. MARINO Z, Darnell A, Lens S, Sapena V, et al
    Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules.
    J Hepatol. 2019 Jan 23. pii: S0168-8278(19)30015.
    PubMed     Text format     Abstract available

    J Med Virol

  8. KWON JH, Yoo SH, Nam SW, Kim HY, et al
    Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea.
    J Med Virol. 2019 Jan 29. doi: 10.1002/jmv.25412.
    PubMed     Text format     Abstract available

    J Viral Hepat

  9. BLADOWSKA J, Pawlowski T, Fleischer-Stepniewska K, Knysz B, et al
    Interferon-free Therapy as the Cause of White Matter Tracts and Cerebral Perfusion Recovery in Patients with Chronic Hepatitis C.
    J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13069.
    PubMed     Text format     Abstract available

  10. JACK K, Thomson BJ, Irving WL
    Testing for hepatitis C virus infection in UK Prisons: what actually happens?
    J Viral Hepat. 2019 Jan 31. doi: 10.1111/jvh.13071.
    PubMed     Text format     Abstract available

    PLoS One

  11. XIAO Y, Shen M, Ma S, Wen SW, et al
    The association between inter-twin birth weight discordance and hepatitis C: The United States 2011-2015 twin birth registration data.
    PLoS One. 2019;14:e0211683.
    PubMed     Text format     Abstract available

  12. SHILI-MASMOUDI S, Sogni P, de Ledinghen V, Esterle L, et al
    Increased liver stiffness is associated with mortality in HIV/HCV coinfected subjects: The French nationwide ANRS CO13 HEPAVIH cohort study.
    PLoS One. 2019;14:e0211286.
    PubMed     Text format     Abstract available

  13. MANGIA A, Losappio R, Cenderello G, Potenza D, et al
    Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis.
    PLoS One. 2018;13:e0200568.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.